KR100599134B1 - 양성 전립선 비대증에 대한 nk-1 수용체 길항물질의 용도 - Google Patents
양성 전립선 비대증에 대한 nk-1 수용체 길항물질의 용도 Download PDFInfo
- Publication number
- KR100599134B1 KR100599134B1 KR1020037013798A KR20037013798A KR100599134B1 KR 100599134 B1 KR100599134 B1 KR 100599134B1 KR 1020037013798 A KR1020037013798 A KR 1020037013798A KR 20037013798 A KR20037013798 A KR 20037013798A KR 100599134 B1 KR100599134 B1 KR 100599134B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- trifluoromethyl
- bis
- tolyl
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
화학식 I의 화합물 | 1㎎ |
1n HCl | 20㎕ |
아세트산 | 0.5㎎ |
NaCl | 8㎎ |
페놀 | 10㎎ |
1n NaOH | pH 5가 되는 적정량 |
H2O | 1㎖가 되는 적정량 |
고환 | 전립선 | |||||
투여 | 100g당 체중 | 대조군과의 차(%) | 100g당 체중 | 대조군과의 차(%) | ||
㎎/㎏/d | 절대 | 상대 | 절대 | 상대 | ||
0/veh | 24.006 | 0.1698 | (=100%) | 11.006 | 0.078 | (=100%) |
6 | 24.577 | 0.1803 | +1% | 8.006 | 0.059 | -24% |
20 | 23.432 | 0.1804 | +6% | 6.413 | 0.049 | -37% |
60 | 24.753 | 0.1853 | +9% | 4.429 | 0.033 | -58% |
Claims (29)
- 삭제
- NK-1 수용체 길항물질 및 약학적으로 허용가능한 부형제를 포함하는, 양성 전립선 비대증의 치료 및/또는 예방을 위한 약학 조성물로서, 상기 NK-1 수용체 길항물질이 하기 화학식 I의 화합물 또는 그의 약학적으로 허용가능한 산 부가염인 것을 특징으로 하는 약학 조성물.화학식 IR은 수소, C1-7 알킬, C1-7 알콕시, 할로겐 또는 트리플루오로메틸이고;R1은 수소 또는 할로겐이거나; 또는R 및 R1이 함께 -CH=CH-CH=CH-일 수 있고;R2 및 R2'는 서로 독립적으로 수소, 할로겐, 트리플루오로메틸, C1-7 알콕시 또는 시아노이거나; 또는R2 및 R2'가 함께 C1-7 알킬 또는 C1-7 알콕시로부터 선택된 1개 또는 2개의 치환기로 선택적으로 치환된 -CH=CH-CH=CH-일 수 있고;R3은 수소, C1-7 알킬이거나, C3-6 사이클로알킬 그룹을 형성할 수 있고;R4는 수소, -N(R5)2, -N(R5)(CH2)nOH-, -N(R5)S(O)2-C1-7 저급 알킬, -N(R5)S(O)2-페닐, -N=CH-N(R5)2, -N(R5)C(O)R5, 그룹 또는 그룹의 사이클릭 3차 아민이거나, 또는 피롤리딘-1-일, 이미다졸-1-일, 피페리딘-1-일, 피페라진-1-일, 몰폴린-4-일, 티오몰폴린-4-일, 1-옥소-티오몰폴린-4-일, 1,1-디옥소-티오몰폴린-4-일, 2,3-디하이드로-[1,4]옥사진-4-일, 또는 [1,2,4]트리아졸-1-일에서 선택되는 것이며;R5는 서로 독립적으로 수소, C3-6 사이클로알킬, 벤질 또는 C1-7 알킬이고;R6은 수소, 하이드록시, C1-7 알킬, -(CH2)nCOO-C1-7 알킬, -N(R5)CO-C1-7 알킬, 하이드록시-C1-7 알킬, 시아노, -(CH2)nO(CH2)nOH, -CHO 이거나, 또는 피리디닐, 피리미디닐, 옥사디아졸릴, 트리아졸릴, 테트라졸릴, 티아졸릴, 티에닐, 푸릴, 피라닐, 피롤릴, 이미다졸릴, 피라졸릴, 이소티아졸릴, 피페라지닐 또는 피페리딜로 구성된 군에서 선택되는, -(CH2)1-7 그룹을 통해 선택적으로 결합되는 5원 또는 6원 헤테로사이클릭 그룹이고;X는 -C(O)N(R5)-, 또는 -N(R5)C(O)-이고;n은 0, 1, 2, 3 또는 4이고;m은 1 또는 2이다.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제 2 항에 있어서,NK-1 수용체 길항물질이, X가 -C(O)N(R5)-이고 R5가 메틸, 에틸 또는 사이클로프로필인 화학식 I의 화합물인, 약학 조성물.
- 제 10 항에 있어서,화합물이,N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-4-o-톨릴-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-4-(2-클로로-페닐)-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-4-(2-트리플루오로메틸-페닐)-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-4-(2-플루오로-페닐)-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-4-(2-메톡시-페닐)-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-4-페닐-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-N-에틸-4-o-톨릴-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-N-사이클로프로필-4-o-톨릴-니코틴아미드,N-[1-(3,5-비스-트리플루오로메틸-페닐)-에틸]-N-메틸-4-o-톨릴-니코틴아미드,N-(3,5-디-플루오로벤질)-N-메틸-4-o-톨릴-니코틴아미드,N-(3,5-디-클로로벤질)-N-메틸-4-o-톨릴-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-6-(4-메틸-피페라진-1-일)-4-o-톨릴-니코틴아미드,2'-메틸-5-(4-메틸-피페라진-1-일)-비페닐-2-카복실산-(3,5-비스-트리플루오로메틸-벤질)-메틸-아미드,N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-6-(4-메틸-피페라진-1-일)-4-나프탈렌-1-일-니코틴아미드,(4-{5-[(3,5-비스-트리플루오로메틸-벤질)-메틸-카바모일]-4-o-톨릴-피리딘-2-일}-피페라진-1-일)-아세트산 에틸 에스테르,5'-[(3,5-비스-트리플루오로메틸-벤질)-메틸-카바모일]-4'-o-톨릴-3,4,5,6-테트라하이드로-2H-[1,2']비피리디닐-4-카복실산 에틸 에스테르,N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-6-(4-프로필-피페라진-1-일)-4-o-톨릴-니코틴아미드,(RS)-6-[3-(아세틸-메틸-아미노)-피롤리딘-1-일]-N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-4-o-톨릴-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-6-[메틸-(2-몰폴린-4-일-에틸)-아미노]-4-o-톨릴-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-6-몰폴린-4-일-4-o-톨릴-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-6-티오몰폴린-4-일-4-o-톨릴-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-6-(1-옥소-1λ4-티오몰폴린-4-일)-4-o-톨릴-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-6-(1,1-디옥소-1λ6-티오몰폴린-4-일)-N-메틸-4-o-톨릴-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-6-피페라진-1-일-4-o-톨릴-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-6-[4-(2-하이드록시-에틸)-피페라진-1-일]-N-메틸-4-o-톨릴-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-6-(4-시아노메틸-피페라진-1-일)-N-메틸-4-o-톨릴-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-6-{4-[2-(2-하이드록시-에톡시)-에틸]-피페라진-1-일}-N-메틸-4-o-톨릴-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-6-(4-[1,2,4]옥사디아졸-3-일-메틸-피페라진-1-일)-4-o-톨릴-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-6-[4-(5-옥소-4,5-디하이드로-1H-[1,2,4]트리아졸-3-일-메틸)-피페라진-1-일]-4-o-톨릴-니코틴아미드,N-(3,5-비스-트리플루오로메틸-벤질)-6-(4-포르밀-피페라진-1-일)-N-메틸-4-o-톨릴-니코틴아미드, 및N-메틸-N-(2-메틸-나프탈렌-1-일-메틸)-6-몰폴린-4-일-4-o-톨릴-니코틴아미드로 이루어진 군으로부터 선택되거나; 또는 이들의 약학적으로 허용가능한 산 부가염인, 약학 조성물.
- 제 2 항에 있어서,NK-1 수용체 길항물질이, X가 -N(R5)-C(O)-이고 R5가 수소 또는 메틸인 화학식 I의 화합물인, 약학 조성물.
- 제 12 항에 있어서,화합물이,2-(3,5-비스-트리플루오로메틸-페닐)-N-메틸-N-[6-(4-메틸-피페라진-1-일)-4-o-톨릴-피리딘-3-일]-이소부티르아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-[4-(2-클로로-페닐)-6-(4-메틸-피페라진-1-일)-피리딘-3-일]-N-메틸-이소부티르아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-[4-(4-플루오로-2-메틸-페닐)-6-(4-메틸-피페라진-1-일)-피리딘-3-일]-N-메틸-이소부티르아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-[4-(2-클로로-페닐)-피리딘-3-일]-N-메틸-이소부티르아미드,2-(3,5-비스-트리플루오로메틸-페닐-N-메틸-N-(4-o-톨릴-피리딘-3-일)-이소부티르아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-(4-o-톨릴-피리딘-3-일)-이소부티르아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-메틸-N-(4-o-톨릴-피리딘-3-일)-아세트아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-메틸-N-(4-o-톨릴-피리딘-3-일)-프로피온아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-메틸-N-(6-몰폴린-4-일-4-o-톨릴-피리딘-3-일)-이소부티르아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-[4-(2-클로로-페닐)-6-몰폴린-4-일-피리딘-3-일]-N-메틸-이소부티르아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-메틸-N-{6-[메틸-(2-몰폴린-4-일-에틸)-아미노]-4-o-톨릴-피리딘-3-일}-이소부티르아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-메틸-N-[6-(4-피리미딘-2-일-피페라진-1-일)-4-o-톨릴-피리딘-3-일]-이소부티르아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-(6-몰폴린-4-일-4-o-톨릴-피리딘-3-일)-이소부티르아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-[4-(2-클로로-페닐)-6-디메틸아미노-피리딘-3-일]-이소부티르아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-메틸-N-(6-피페라진-1-일-4-o-톨릴-피리딘-3-일)-이소부티르아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-(4-하이드록시-4'-o-톨릴-3,4,5,6-테트라하이드로-2H-[1,2']비피리디닐-5'-일)-N-메틸-이소부티르아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-{6-[(2-하이드록시-에틸)-메틸-아미노]-4-o-톨릴-피리딘-3-일}-N-메틸-이소부티르아미드,(R)-2-(3,5-비스-트리플루오로메틸-페닐)-N-[6-(3-하이드록시-피롤리딘-1-일)-4-o-톨릴-피리딘-3-일]-N-메틸-이소부티르아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-메틸-N-(6-몰폴린-4-일-4-o-톨릴-피리딘-3-일)-아세트아미드, 및[2-(3,5-비스-트리플루오로메틸-페닐)-2-메틸-프로필]-[4-(4-플루오로-2-메틸-페닐)-6-(4-메틸-피페라진-1-일)-피리딘-3-일]-메틸아민으로 이루어진 군으로부터 선택되거나; 또는 이들의 약학적으로 허용가능한 산 부가염인, 약학 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제 2 항에 있어서,NK-1 수용체 길항물질이 2-(3,5-비스-트리플루오로메틸-페닐)-N-메틸-N-(6-몰폴린-4-일-4-o-톨릴-피리딘-3-일)-이소부티르아미드 또는 그의 약학적으로 허용가능한 산 부가염인, 약학 조성물.
- 제 2 항에 있어서,NK-1 수용체 길항물질이2-(3,5-비스-트리플루오로메틸-페닐)-N-메틸-N-[6-(4-메틸-피페라진-1-일)-4-o-톨릴-피리딘-3-일]-이소부티르아미드,2-(3,5-비스-트리플루오로메틸-페닐)-N-[6-(1,1-디옥소-1λ6-티오몰폴린-4-일)-4-o-톨릴-피리딘-3-일]-N-메틸-이소부티르아미드, 또는2-(3,5-비스-트리플루오로메틸-페닐)-N-[6-(1,1-디옥소-1λ6-티오몰폴린-4-일)-4-(4-플루오로-2-메틸-페닐)-피리딘-3-일]-N-메틸-이소부티르아미드; 또는이들의 약학적으로 허용가능한 산 부가염인, 약학 조성물.
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01109853 | 2001-04-23 | ||
EP01109853.0 | 2001-04-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040007503A KR20040007503A (ko) | 2004-01-24 |
KR100599134B1 true KR100599134B1 (ko) | 2006-07-12 |
Family
ID=8177209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037013798A KR100599134B1 (ko) | 2001-04-23 | 2002-02-02 | 양성 전립선 비대증에 대한 nk-1 수용체 길항물질의 용도 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20030004157A1 (ko) |
EP (1) | EP1385577B1 (ko) |
JP (1) | JP4146730B2 (ko) |
KR (1) | KR100599134B1 (ko) |
CN (1) | CN100398106C (ko) |
AR (1) | AR035935A1 (ko) |
AT (1) | ATE323531T1 (ko) |
AU (1) | AU2002250876B2 (ko) |
BR (1) | BR0209151A (ko) |
CA (1) | CA2444395C (ko) |
DE (1) | DE60210760T2 (ko) |
DK (1) | DK1385577T3 (ko) |
ES (1) | ES2261657T3 (ko) |
MX (1) | MXPA03009720A (ko) |
PT (1) | PT1385577E (ko) |
WO (1) | WO2002085458A2 (ko) |
ZA (1) | ZA200308110B (ko) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002089802A2 (en) * | 2001-05-08 | 2002-11-14 | Schering Corporation | Use of neurokinin receptor antagonists to treat androgen-dependent diseases |
US6849624B2 (en) | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
NZ541243A (en) * | 2003-01-31 | 2008-04-30 | Hoffmann La Roche | New crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide |
JP4490421B2 (ja) * | 2003-07-03 | 2010-06-23 | エフ.ホフマン−ラ ロシュ アーゲー | 統合失調症を処置するデュアルnk1/nk3アンタゴニスト |
ES2246687B2 (es) * | 2004-02-11 | 2006-11-16 | Miguel Muñoz Saez | Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales. |
JP4580426B2 (ja) | 2004-07-06 | 2010-11-10 | エフ.ホフマン−ラ ロシュ アーゲー | Nk−1受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法 |
US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
EP1855655A2 (en) | 2005-02-25 | 2007-11-21 | F. Hoffmann-Roche AG | Tablets with improved drug substance dispersibility |
SI2395002T1 (sl) | 2005-11-08 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
JP5497633B2 (ja) | 2007-05-09 | 2014-05-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftrのモジュレーター |
SI2225230T1 (sl) | 2007-12-07 | 2017-03-31 | Vertex Pharmaceuticals Incorporated | Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline |
PL2639223T3 (pl) | 2007-12-07 | 2017-09-29 | Vertex Pharmaceuticals Incorporated | Sposób wytwarzania kwasów cykloalkilokarboksyamido-pirydyno-benzoesowych |
CA2931134C (en) | 2008-02-28 | 2019-07-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
WO2010106988A1 (ja) | 2009-03-17 | 2010-09-23 | 第一三共株式会社 | アミド誘導体 |
WO2010119347A1 (en) * | 2009-04-14 | 2010-10-21 | Helsinn Healthcare S.A. | Netupitant for use in treating bladder dysfunction |
EP2493299A4 (en) * | 2009-10-29 | 2013-04-17 | Merck Sharp & Dohme | TERTIARY AMIDOREXIN RECEPTOR ANTAGONISTS |
JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の医薬組成物およびその投与 |
EP3067349B1 (en) | 2013-11-08 | 2018-02-28 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
RU2016122882A (ru) | 2013-11-12 | 2017-12-19 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
RU2691136C2 (ru) | 2014-11-18 | 2019-06-11 | Вертекс Фармасьютикалз Инкорпорейтед | Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии |
EP3746077A4 (en) * | 2018-02-02 | 2021-10-27 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | PARENTERAL FORMULATIONS AND USES THEREOF |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6175013B1 (en) * | 1994-06-10 | 2001-01-16 | Eli Lilly And Company | Imidazolinyl tachykinin receptor antagonists |
FR2729951B1 (fr) * | 1995-01-30 | 1997-04-18 | Sanofi Sa | Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant |
CN1272842A (zh) * | 1997-08-06 | 2000-11-08 | 伊莱利利公司 | 作为速激肽受体拮抗剂的2-酰氨基丙胺类化合物 |
IL134155A0 (en) * | 1997-08-06 | 2001-04-30 | Lilly Co Eli | 2-acylaminopropanamines as tachykinin receptor antagonists |
JPH11322748A (ja) * | 1998-03-19 | 1999-11-24 | Takeda Chem Ind Ltd | 複素環化合物、その製造法および用途 |
EP1035115B1 (en) * | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
AU3735000A (en) * | 1999-05-05 | 2000-11-21 | Warner-Lambert Company | Modulation of substance p by gaba analogs and methods relating thereto |
WO2002006236A1 (en) * | 2000-07-14 | 2002-01-24 | F. Hoffmann-La Roche Ag | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
US6849624B2 (en) * | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
-
2002
- 2002-02-02 CA CA2444395A patent/CA2444395C/en not_active Expired - Lifetime
- 2002-02-02 DE DE60210760T patent/DE60210760T2/de not_active Expired - Lifetime
- 2002-02-02 CN CNB028087305A patent/CN100398106C/zh not_active Expired - Lifetime
- 2002-02-02 ES ES02719751T patent/ES2261657T3/es not_active Expired - Lifetime
- 2002-02-02 AT AT02719751T patent/ATE323531T1/de active
- 2002-02-02 WO PCT/EP2002/001085 patent/WO2002085458A2/en active IP Right Grant
- 2002-02-02 BR BR0209151-8A patent/BR0209151A/pt not_active Application Discontinuation
- 2002-02-02 EP EP02719751A patent/EP1385577B1/en not_active Expired - Lifetime
- 2002-02-02 PT PT02719751T patent/PT1385577E/pt unknown
- 2002-02-02 JP JP2002583031A patent/JP4146730B2/ja not_active Expired - Lifetime
- 2002-02-02 DK DK02719751T patent/DK1385577T3/da active
- 2002-02-02 KR KR1020037013798A patent/KR100599134B1/ko active IP Right Grant
- 2002-02-02 AU AU2002250876A patent/AU2002250876B2/en not_active Expired
- 2002-02-02 MX MXPA03009720A patent/MXPA03009720A/es active IP Right Grant
- 2002-02-07 AR ARP020100393A patent/AR035935A1/es unknown
- 2002-02-08 US US10/071,570 patent/US20030004157A1/en not_active Abandoned
-
2003
- 2003-10-17 ZA ZA2003/08110A patent/ZA200308110B/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR0209151A (pt) | 2004-07-13 |
DE60210760D1 (de) | 2006-05-24 |
CN1503684A (zh) | 2004-06-09 |
WO2002085458A3 (en) | 2003-10-30 |
CA2444395A1 (en) | 2002-10-31 |
PT1385577E (pt) | 2006-08-31 |
ES2261657T3 (es) | 2006-11-16 |
AU2002250876B2 (en) | 2005-03-03 |
EP1385577A2 (en) | 2004-02-04 |
CN100398106C (zh) | 2008-07-02 |
MXPA03009720A (es) | 2004-01-29 |
AR035935A1 (es) | 2004-07-28 |
WO2002085458A2 (en) | 2002-10-31 |
KR20040007503A (ko) | 2004-01-24 |
EP1385577B1 (en) | 2006-04-19 |
DE60210760T2 (de) | 2006-11-23 |
ATE323531T1 (de) | 2006-05-15 |
US20030004157A1 (en) | 2003-01-02 |
CA2444395C (en) | 2010-12-21 |
JP4146730B2 (ja) | 2008-09-10 |
DK1385577T3 (da) | 2006-08-21 |
JP2004529931A (ja) | 2004-09-30 |
ZA200308110B (en) | 2005-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100599134B1 (ko) | 양성 전립선 비대증에 대한 nk-1 수용체 길항물질의 용도 | |
AU2002250876A1 (en) | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | |
KR100589106B1 (ko) | 뇌, 척추 또는 신경 손상을 치료하기 위한 nk-1 수용체길항제의 용도 | |
AU2002328837A1 (en) | Use of NK-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury | |
EP0710479B1 (en) | Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine | |
JPH08505637A (ja) | Nk1およびnk2レセプターについての拮抗薬効果を有する相乗的組み合わせ物 | |
EP0747049A1 (en) | Use of tachykinin antagonists in combination with serotonin agonists or serotonin reuptake inhibitors for the manufacture of a medicament for the treatment of allergic rhinitis | |
JP2000510155A (ja) | 医薬製剤 | |
KR20060130619A (ko) | 유기 화합물의 조합물 | |
EP0747055A2 (en) | Use of tachykinin receptors antagonists for the treatment of cold and allergic rhinitis | |
US6197796B1 (en) | Anticancer composition comprising a diaminotrifluoromethylpyridine derivative | |
JP2002504134A (ja) | 疼痛を治療するためのドラフラジン類似体の使用 | |
JP2002527381A (ja) | アレルギー性疾患を処置するための組成物および方法 | |
US5846973A (en) | Methods of treating pulmonary hypertension | |
WO2019124488A1 (ja) | セペタプロストとRhoキナーゼ阻害剤との組み合わせ医薬 | |
US6001837A (en) | Methods of treating or preventing sleep apnea | |
TWI303991B (en) | Use of nk-1 receptor antagonists for the treatment of brain,spinal or nerve injury | |
WO1997044035A1 (en) | Methods of treating hypertension |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130628 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140627 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160629 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170629 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180628 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190624 Year of fee payment: 14 |